Skip to main content

Advertisement

Table 2 Arm A (vaccine + IL-2): patient profiles, clinical, and immunological outcomes

From: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Pt Age Cancer Stage on enrollment # of cycles Off-study reason PFS#(ms) OS* (ms) Immune response
Proliferative assay Elispot
         Pre-vaccine Post-vaccine Pre-vaccine Post-vaccine
1A 56 Colon IV 2 PD 0.5 5.5 ND
2A 57 Colon IV 3 PD 3.9 16.8 NA - -
3A 62 Colon IV 3 PD 5.8 21.5 - - - -
4A 50 Pancreatic IV 3 PD 3.6 6.2 - - - -
5A 60 Lung IV 1 PD 1 2.8 ND
6A 59 Colon IV 3 PD 3.5 8.9 NA
7A 52 Colon NED 11 Completed 129+ 129+ - + - +
8A 68 Lung IV 3 PD 3.6 13.1 - - - -
9A 56 Colon NED 10 PPS 18.8 37.2 - + - +
10A 63 Colon IV 3 PD 3.3 19.9 - - - -
11A 42 Pancreatic NED 6 PD 7.5 24.1 - - - -
12A 39 Colon NED 3 PD 6.2 23 - - - -
13A 67 Colon IV 3 PD 3.5 4.8 - + + +
14A 51 Colon NED 3 PD 7.1 41.3 - - - -
15A 60 Pancreatic IV 3 PPS/Lost to follow-up 2.7+ 5.3 NA - -
16A 61 Colon IV 3 PD 3.6 17.3 - + - -
  1. #Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
  2. Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.